Featured Stories

6:28 PM Apr 20, 2018
Redrawing the lines

Word that Merck & Co. Inc.’s Keytruda pembrolizumab had “won” the first-line lung cancer showdown with Bristol-Myers Squibb Co. at AACR spread quickly on Monday, but there was little discussion among investors and in the media about the implications for clinical practice and future development.

Oncologists told BioCentury that in addition to...

4:45 PM Apr 20, 2018
Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of which will see companies and patients punished for sticking with traditional trial designs rather than adopting novel formats with better chances of predicting Phase III...

BioCentury Management

Karen Bernstein, Ph.D., Co-Founder & Chairman

Karen is co-founder and chairman of BioCentury Inc. and was Editor-in-Chief from October 1992 to August 2015. She is a director at Ovid Therapeutics Inc., which is focused on developing drugs for orphan diseases of the brain, and at Achaogen Inc., which is developing drugs to treat multi-drug resistant gram-negative infections. She is on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council. In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Karen into their Hall of Fame, citing her lifetime contribution to the biotech community. In 2007, Karen received a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2013, she was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2015, Scientific American named Karen as one of The WorldVIEW 100 most influential people in biotech today. In 2016, she was named Commentator of the Year by the European Mediscience Awards.

David Flores, Co-Founder, President & CEO 

David has devoted more than 25 years to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University. David is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board. In 1996, David and BioCentury Co-Founder & Chairman Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, Calif., citing BioCentury's ongoing contributions to the industry.

Thomas Carey, Vice President of Commercial Operations

Tom joined BioCentury in 2008 as Vice President of Commercial Operations. He has over 20 years of commercial experience in the pharmaceutical and biotech industry, serving in leadership roles in sales, marketing, product planning and business development. Tom was Senior Vice President of Sales and Marketing for Connetics, a specialty dermatology company now part of GlaxoSmithKline. He also was Vice President of Professional Sales as well as Vice President of Business Development at the OrthoNeutrogena division of Ortho-McNeil Pharmaceuticals, a Johnson & Johnson company. Tom's background also includes senior management positions at Roche Laboratories and Syntex Corp., which was acquired by Roche in 1994. He holds a bachelor's degree and an MBA from the University of California at Berkeley.

Bennet Weintraub, Vice President & Chief Financial Officer

Bennet Weintraub, Vice President & Chief Financial Officer Bennet, who joined BioCentury in 2004, has had an extensive career as a senior financial executive for development stage biotechnology and technology companies, having taken two companies public, and having completed numerous equity and debt financings and M&A transactions. He was CFO at InterMune, Valentis and Technology Modeling Associates, and held senior financial positions at Metra Biosystems and Advanced Polymer Systems. Bennet received his B.A. in Mathematical Economics from Pomona College and earned his MBA from Harvard University.

Eric Pierce, Publisher

Eric joined BioCentury in 1993 as its first Staff Writer, and became chief financial writer in 1996 when he originated "Ebb & Flow," BioCentury's weekly capital markets column. As Senior Editor for News, Eric managed BioCentury's news operations until 2004, when he joined the management team as Associate Publisher, and in 2007 was named Publisher. He holds an A.B. in Communication from Stanford University and completed graduate studies at the Mass Media Institute at Stanford, with an emphasis on broadcast journalism.

Susan Morgan, Director of Administration & Human Resources

Susan joined BioCentury in 2006, bringing with her extensive experience in the legal profession in New York. She holds a B.A. in Political Science from Fairfield University and a J.D. from Fordham University School of Law.